Acetaminophen, a common analgesic/antipyretic, is a frequent cause of acute liver failure in Western countries. The development of an effective cure against acetaminophen hepatotoxicity is crucial. Ethyl pyruvate, an ethyl ester derivative of pyruvic acid, has been identified as a possible candidate against acetaminophen hepatotoxicity in animal experiments. However, the mode of the hepatoprotective action of ethyl pyruvate remains unclear. We examined the hepatoprotective effect of ethyl pyruvate against hepatocyte injury and oxidative stress in a mouse model of acetaminophen hepatotoxicity. In addition, to examine whether ethyl pyruvate has direct hepatocellular protection against acetaminophen hepatotoxicity to counteract the influence of inflammatory cells, such as macrophages, we examined the effects of ethyl pyruvate on cellular injury induced by N-acetyl-p-benzoquinone imine, a toxic metabolite of acetaminophen, in a human hepatocyte cell line, HepG2 cells. Treatment with ethyl pyruvate significantly prevented increases in serum transaminase levels and hepatic centrilobular necrosis induced with an acetaminophen overdose in mice in a dose-dependent manner. Although hepatic DNA fragmentation induced by acetaminophen was also attenuated with ethyl pyruvate, nitrotyrosine formation was not inhibited. Ehyl pyruvate significantly attenuated mitochondria dehydrogenase inactivity induced by N-acetyl-p-benzoquinone imine in HepG2 cells.
physiological properties including potent anti-inflammatory and anti-oxidative effects [19, 20, 21] . Yang et al. reported that EtPy inhibited increases in transaminase levels and tumor necrosis factor (TNF)-α concentrations in serum, hepatic centrilobular necrosis, and infiltration of inflammatory cells in a mouse model of APAP-overdose, and suggested the preventive effects of EtPy against APAP hepatitis in mice. Suppressive effects of EtPy on activated inflammatory cells, such as macrophages and neutrophils, and reduction of cytokine release from cells, such as TNF-α, may be involved in the hepatoprotective mechanism of EtPy.
However, EtPy also has a scavenger action against reactive oxygen species, such as hydrogen peroxide, and cytoprotective potential against cellular injury through anti-apoptotic and necroptotic effects [22, 23, 24] . Therefore, it is suggested that the antioxidative action and direct hepatocyte protection by EtPy against NAPQIinduced hepatocyte injury without inhibiting inflammatory cells should be considered. Little is reported on the hepatoprotective effects of EtPy in APAPinduced liver injury models.
This study was conducted to evaluate the hepatoprotective action of EtPy against APAP hepatotoxicity with regard to its antioxidative and cytoprotective effects.
Using a mouse model of APAP hepatotoxicity, we examined the effects of EtPy on the increase in serum transaminase levels, centrilobular necrosis, DNA fragmentation, and nitrotyrosine formation in the liver. We also conducted an in vitro study to determine the scavenger potential of EtPy against reactive oxygen species, such as hydroxyl radicals and peroxynitrite, which play important roles in the development of APAP liver injury. In addition, we evaluated whether EtPy shows direct hepatocyte protection during APAP-induced liver injury using an in vitro system to counteract the influences of inflammatory cells, such as macrophages and neutrophils. We examined the effects of EtPy on NAPQIinduced cell injury in a representative hepatocellular model mainly using mainly HepG2 cells, a human hepatoma cell line. Then we compared the effects of EtPy with pyruvic acid (PyA), a parent compound of EtPy, and phosphopyruvic acid (PEP), a precursor of PyA in glycolysis, against NAPQI-induced cell injury.
Materials and methods
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Systems (Minneapolis, MN). All other reagents and solvents were of reagent grade.
Deionized and distilled bio-pure grade water was used in the study.
Animal experiments
Animals
Male wild-type C57BL/6JJcl mice (8-10 weeks old) (CLEA Japan, Shiga, Japan) were used. Animals were housed in cages under controlled conditions at 24°C on a 12-h light/dark cycle and had free access to food and water. All experimental procedures conformed with the Animal Use Guidelines of the Committee for Ethics on Animal Experiments at Kumamoto University. The study protocol was approved by the ethical committee (the name of committee: "Animal Care and Use Committee of Kumamoto University", The approval No.: B27-131 and A29-132).
Experimental settings and treatments
The mouse model of APAP hepatitis was developed as described previously [13, 25, 26] . Briefly, APAP was dissolved in phosphate-buffered saline at 55-60°C and prepared in a 2% solution. An overdose of APAP (400 mg/kg) was intraperitoneally injected into mice to induce hepatotoxicity. EtPy was dissolved in Ringer's solution and administered intraperitoneally at 0.5, 2, 4, and 6 h after the APAP injection. Animals were divided by three groups: (1) a vehicle group; (2) a lowdose EtPy (50 mg/kg) group; and (3) a high-dose EtPy (100 mg/kg) group. A treatment schedule is provided in Fig. 1A . Mice in the low-dose EtPy (50 mg/kg) group were treated with 20 mg/kg EtPy at 0.5 h after the APAP injection, and 10 mg/kg of EtPy (three times in total) at 2, 4, and 6 h after the injection. Mice in the high-dose EtPy (100 mg/kg) group were treated with 40 mg/kg EtPy at 0.5 h after the APAP injection, and 20 mg/kg of EtPy (three times in total) at 2, 4, and 6 h after the injection. Mice in the vehicle group were administered Ringer's solution (1 μL/g body weight) at 0.5, 2, 4, and 6 h after the APAP injection. Mice were killed at 8 h after the APAP injection and blood and tissue samples were collected.
Evaluation of liver injury
The protective effects of EtPy were evaluated by examining serum alanine aminotransferase (ALT) and aspartate transaminase (AST) levels, and histological analysis using hematoxylin and eosin staining of samples. DNA fragmentation and nitrotyrosine formation were evaluated using the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay and immunohistochemistry, respectively. The assay was performed as described previously [13, 26] . Blood samples was centrifuged at 4000 × g at 4°C for 10 min after coagulation and serum was collected. Serum ALT and AST levels were determined using a bioanalyzer (SPOTCHEM EZ SP-4430; ARKRAY, Kyoto, Japan). Liver tissue samples 
Development of the model of NAPQI-induced hepatocellular injury
Cellular injury induced by NAPQI was evaluated using methods described previously [12, 27] . HepG2 or RLC cells were seeded at 1 × 10 4 cells/well into a 96-well plate. 
Evaluation of peroxynitrite and hydroxyl radicals scavenging activity
To determine the antioxidative effects of EtPy, we evaluated the scavenging activity against peroxynitrite and hydroxyl radicals ( • OH), which play important roles in the development of APAP hepatotoxicity. The methods have been described previously [28] . We used dihydrorhodamine, a reduced form of rhodamine, as a probe for peroxynitrite activity to examine the scavenging effect of EtPy. Peroxynitrite was diluted with 0.3 M NaOH to give a 7-mL solution. A mixture containing 100 mL sodium phosphate buffer (pH 7.4), 0.3 mg/mL gelatin, 25 mL dihydrorhodamine, and EtPy was pre-incubated at 37°C for 5 min, and the reaction was started by adding 200 mL of the mixture to 2 mL of peroxynitrite solution. After incubation at 37°C for 5 min, the generated rhodamine was estimated using the above-described fluorescence measurements. A peroxynitritedependent increase in fluorescence was then converted into the rhodamine concentration from the external rhodamine standard.
• OH was generated using an H 2 O 2 /ultraviolet (UV) radiation system and was ) signal, in which Mn 2+ served as an internal control. An EPR spectrum of DMPO spin adducts of • OH was generated, and the relative quantification of the scavenging activity was evaluated using DMPO spin adduct intensities of • OH.
Statistical analysis
Statistical analyses were performed using GraphPad Prism (ver. 5.01; GraphPad Software, San Diego, CA). Multiple comparisons were used to examine the statistical significance of the data. When uniform variance was identified using Bartlett's analysis (P > 0.05), one-way analysis of variance (ANOVA) was used to test for statistical significance. When significant differences (P < 0.05) were identified, data were further analyzed using the Tukey (or Tukey-Kramer) multiple range test, as appropriate.
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Attenuating effects of EtPy against APAP-induced liver injury in mice
To confirm the effects of EtPy against APAP hepatotoxicity, we used a mouse model of liver injury induced by an overdose of APAP. Mice were treated with multiple doses of EtPy after the APAP injection, for totals of 50 and 100 mg/kg of EtPy for each group (Fig. 1A) . Treatment with EtPy significantly reduced serum ALT and AST levels at 8 h after the APAP injection (Fig. 1B) . In the vehicle treatment group, numerous areas of centrilobular necrosis with bleeding were observed, which is a typical manifestation of APAP hepatotoxicity ( Fig. 1C; left) .
Although slight histological changes, such as swelling of hepatocytes around central veins, were observed, little centrilobular necrosis was visible in both EtPy groups (Fig. 1C) .
To investigate the effects of EtPy on nuclear DNA fragmentation, the TUNEL assay was performed. As shown in Fig. 2A , many lobes in the vehicle group showed some TUNEL-stained cells. In contrast, only a few TUNEL-positive cells were visible in the EtPy groups.
Hepatic nitrotyrosine adduct formation was evaluated using immunohistochemical staining for nitrotyrosine in hepatic histological sections. Extensive nitrotyrosine staining of centrilobular hepatocytes was observed in all groups (Fig. 2B) . Treatment with EtPy did not seem to inhibit the nitrotyrosine adduct formation induced by APAP.
Preventive effects of EtPy on the decrease in mitochondrial dehydrogenase activity induced by NAPQI in HepG2 and RLC cells
To evaluate the cytoprotective potential of EtPy against hepatocellular injury induced by NAPQI, a toxic metabolite of APAP, we examined the effects of EtPy on mitochondrial dehydrogenase activity in NAPQI-treated HepG2 and RLC cells. A significant decrease in mitochondrial dehydrogenase activity was observed with NAPQI treatment in HepG2 cells (Fig. 3A) . Treatment with EtPy significantly prevented the decrease in mitochondrial dehydrogenase activity induced by NAPQI in a dose-dependent manner in the cells. These preventive effects exerted by 1 mM EtPy were comparable with the effects of 1 mM NAC, a therapeutic antidote against APAP hepatotoxicity. The same preventive effect of EtPy was observed in another hepatocellular model using a rat hepatocellular cell line (RLC cells) (Fig. 4) . of annexin V-stained cells (Fig. 6B ) and annexin V-propidium iodide doublestained cells (Fig. 6C) . The attenuating effects were comparable with the effects of NAC (Fig. 6A , lower right). Although PyA (1 mM) also tended to prevent the increase in annexin V and/or propidium iodide fluorescence, no statistically significant differences were observed. PEP did not show any significant effects on annexin V and propidium iodide fluorescence intensities in NAPQI-treated HepG2 cells.
Evaluation of peroxynitrite and hydroxyl radicals scavenging activity
As shown in [ 
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Discussion
EtPy has been identified as a possible antidote against APAP-induced hepatotoxicity in mouse models [18] . However, the precise mechanism of the in vivo hepatoprotective action of EtPy remains unclear. In this study, we confirmed that EtPy prevented serum transaminase elevation, hepatocellular centrilobular necrosis, and DNA fragmentation, but did not prevent nitrotyrosine adduct formation, induced by APAP in mice. The results support the previous report by Yang et al. [18] , and suggest the preventive mode by which EtPy attenuates APAP hepatotoxicity, at least in part, through the inhibition of hepatocellular injury without oxidative stress.
Another objective of this study was to assess whether EtPy has a direct hepatocellular protective effect against cellular injury induced by NAPQI, a highly reactive toxic metabolite of APAP, in an in vitro hepatocellular experimental system. In this study, we found that EtPy prevented changes in cellular injury parameters, such as mitochondria dehydrogenase inactivity, and increases in annexin V and propidium iodide fluorescence intensities induced by NAPQI treatment in HepG2 cells. The results indicate that EtPy has protective potential against cellular injury induced by NAPQI in cultured hepatic cell models.
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( F i g . _ 5 ) T D $ F I G ]
Article No~e00521
Numerous previous studies have demonstrated the potent anti-inflammatory potential of EtPy [19, 23] . EtPy can inhibit the release of cytokines from macrophages, such as TNF-α and IL-6 [19] , and reactive oxygen species [29, 30] , which are associated with the development of APAP-induced liver injury in mice [18] . Therefore, these anti-inflammatory properties of EtPy seem to play an important role in the attenuation of hepatitis observed in APAP-overdosed mice;
that is "indirect" hepatocyte protection of EtPy exerted through inhibition of macrophages, cytokines, and reactive oxygen species.
Oxidative stress is an important factor in APAP hepatotoxicity, and mitochondrial oxidative stress seems to play a critical role in the development of hepatotoxicity [9] . Jaeschke et al. [31, 32] reported that nitrotyrosine formation is a marker of mitochondrial oxidative stress in APAP-induced liver injury. Nitric oxide reacts with superoxide in mitochondria and forms the reactive nitrogen peroxynitrite, which can then bind to the tyrosine residue of cellular proteins and develop into nitrotyrosine. Previously, we found that hydrophilic C60(OH)10 nanoparticles can attenuate APAP hepatotoxicity via a potent scavenger action against reactive oxygen and nitrogen, including peroxynitrite [26] . In this study, although extensive nitrotyrosine formation was observed in hepatocytes around central veins, EtPy did not inhibit nitrotyrosine formation in the mouse liver. Consistent with previous reports, we also found that EtPy showed a scavenger effect against peroxynitrite and hydroxyl radicals. Although the effects were statistically significant, higher concentrations were needed than the concentration required to exert a cytoprotective effect. From this, we consider that peroxynitrite and hydroxyl radicals may not be a main target molecule of EtPy in the protection against APAP hepatotoxicity. Further studies are needed on this point.
The results also indicate that inhibition of hepatocellular death induced by NAPQI may also be involved in antidote potential of EtPy against APAP hepatitis. The preventive effects of EtPy against NAPQI-induced cellular injury were comparable with the effects of NAC, an approved drug for APAP hepatitis, in this study. The results also suggest that EtPy is an attractive therapeutic candidate against APAP hepatotoxicity.
NAC seems to detoxify NAPQI toxicity through glutathione supplementation and an anti-oxidative action during APAP hepatotoxicity [33, 34, 35] . Wang et al. [22] demonstrated that EtPy has a preventive action on dopamine-induced cell death in PC12 cells, which may be because of the anti-apoptosis action of EtPy. Some in vivo studies suggest anti-apoptotic and/or necrotic effects of EtPy. In the current study, EtPy inhibited the increase in annexin V-and/or propidium iodide-stained cells in NAPQItreated HepG2 cells. Annexin V stain is a representative marker for apoptosis-or necrosis-like dead cells. Therefore, EtPy may attenuate cellular injury induced by NAPQI through the inhibition of an apoptosis-or necrosis-like cell death pathway.
PyA, a parent compound of EtPy, and PEP, a precursor of PyA, have been demonstrated to show anti-inflammatory and anti-oxidative potential in previous studies [28, 36, 37, 38] . Although PEP did not show significant protection against NAPQI-induced cellular injury, PyA tended to attenuate the cytotoxicity induced by NAPQI in the current study. Therefore, the protective action of EtPy might be derived from the parent compound, PyA.
It is known that PyA rapidly forms parapyruvate, a potent inhibitor of the Krebs cycle, via an aldol-like condensation reaction in aqueous solution [23] . Therefore, the use of PyA per se as a therapeutic reagent is problematic; EtPy has been developed to circumvent this problem. Indeed, EtPy has been demonstrated to be a suitable derivative with the inherent advantages of PyA as an anti-inflammatory and anti-oxidative drug [21, 23] . Clinical trials on EtPy have been performed to evaluate the safety and therapeutic effects in high-risk cardiac surgery patients with systemic inflammation and in horses [39, 40] . Although no significant therapeutic benefit has been identified in clinical trials to date, the possibility of the clinical use of EtPy cannot be denied because of its safety observed in the trials. Further studies are necessary to evaluate the clinical benefits in other diseases. From previous and current findings, we suggest that EtPy should be investigated for its potential benefits as a new drug in patients with APAP overdose.
In this study, while we observed the attenuating effects of EtPy in mouse and cellular models of APAP-induced liver injury, the study does have some limitations. First, the protective mechanism of EtPy against APAP hepatotoxicity was not fully clarified in this study. We first thought that inhibition of oxidative stress, particularly with regard to nitrotyrosine formation, was a central part of the protective mechanism of EtPy. However, treatment with EtPy did not inhibit nitrotyrosine formation in the mouse liver treated with APAP. Therefore, we now consider that other factors in APAP hepatotoxicity, such as mitophagy [41, 42] , endoplasmic reticulum stress [13, 43] , DNA fragmentation by endonuclease G, and apoptosis-inducing factor [31, 44, 45] , may be critical targets of EtPy. Further studies are needed to clarify the precise mechanism. Second, we used mitochondrial dehydrogenase activity as a measure of cellular dysfunction. Although mitochondrial dehydrogenase activity measured using WST or MTT assays has been used as a parameter in viable cells, it does not always reflect cell viability. Studies have indicated that cellular mitochondrial dehydrogenase activity was inhibited without cell death under certain experimental conditions [46, 47, 48] .
Indeed, we also observed inconsistencies in the results between mitochondrial dehydrogenase activity and the annexin V/PI assay in this study. Therefore, the decrease in mitochondrial dehydrogenase activity observed in NAPQI-treated cells may indicate other phenomena, such as mitochondrial dysfunction, rather than only cell death. Third, to evaluate the direct hepatoprotective effect of EtPy against NAPQI-induced toxicity, we used immortalized human hepatoma HepG2 cells for the hepatocyte model. Although HepG2 cells are used as a hepatocellular model, there seems to be some weakness when used in an APAP hepatotoxicity model [49] . HepG2 cells show lower expression of CYP2E1 and do not react well to APAP treatment. Antidote NAC cannot protect HepG2 cell injury induced by APAP [50] . Therefore, the mode of cell death in HepG2 cells induced by APAP was quite different when compared with that of primary cultured hepatocytes [49] . In the current study, we used an active metabolite NAPQI instead of APAP to induce cytotoxicity in HepG2 cells, and observed preventive effects with NAC as well as
EtPy. The cytoprotective action of EtPy and NAC was also confirmed in another cell line (RLC cells). Even though the experimental system using NAPQI does have some limitations, the results suggest that EtPy has cytoprotective potential against NAPQI in cells. Further studies are needed to determine the direct hepatocyte protective effect of EtPy and the mode of action using other models, such as human primary hepatocytes or pluripotent stem cell derived hepatocytes [51] .
Conclusion
We confirmed that EtPy showed hepatoprotective action against APAP hepatitis in mice. Although hepatic DNA fragmentation was inhibited with EtPy treatment in mice, nitrotyrosine formation was not prevented. EtPy also significantly attenuated cellular injury induced by NAPQI, an active toxic metabolite of APAP, in hepatic cell lines. The results suggest that the protective potential of EtPy against APAP hepatotoxicity observed in animal models is exerted, at least in part, through direct hepatocellular protection against NAPQI.
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